FDA panel recommends Sage's postpartum depression treatment

FDA panel recommends Sage's postpartum depression treatment

Elsewhere in biotech

(JENNIFER KEEFE/STAT)



Sage Therapeutics checked an important box on its quest to develop new therapies for depression, while Alkermes got a decisive-sounding rejection on a similar effort. And that was reason to update our emoji-enabled scorecard, which keeps tabs on the outcomes of biotech’s biggest binary events.

Still to come this quarter: Does Neurocrine Biosciences’ drug work in Tourette syndrome? Can Spark Therapeutics win back investors with positive gene therapy data? And who will be the next CEO of Gilead Sciences.